Trials / Recruiting
RecruitingNCT07482592
Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
Phase I Clinical Trial to Evaluate the Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 156 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3205 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3205 capsules.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3205 capsules | TQB3205 capsule is a targeted protein degrader |
Timeline
- Start date
- 2026-04-15
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
- First posted
- 2026-03-19
- Last updated
- 2026-04-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07482592. Inclusion in this directory is not an endorsement.